Last updated: May 5, 2026
What is HEPLISAV-B and who markets it?
HEPLISAV-B is a recombinant hepatitis B vaccine (HBV) designed for immunization against hepatitis B virus. It is marketed in the US by Dynavax Technologies, now part of or associated with its commercial platform through corporate arrangements under the Dynavax brand.
What is the clinical trial and regulatory status of HEPLISAV-B?
HEPLISAV-B’s pivotal clinical program for licensure is anchored by large randomized studies evaluating seroprotection against hepatitis B surface antigen (anti-HBs). The key regulatory endpoint in HBV vaccine development is seroprotection, typically defined as anti-HBs titers at or above a specified threshold after completion of the vaccination series.
Key clinical evidence (pivotal program themes)
- Immunogenicity focus: HEPLISAV-B targets higher rates of protective anti-HBs responses compared with prior comparator vaccines, including in populations with traditionally lower vaccine responsiveness.
- Schedule convenience: HEPLISAV-B is administered as a 2-dose series (vs common 3-dose regimens), which increases real-world completion potential.
Labeled clinical use context
HEPLISAV-B is positioned for vaccination against hepatitis B for indicated age groups and risk categories per its US prescribing information labeling. (Labeling details are consolidated through FDA review and the current commercial label.) [1]
What is driving demand for HEPLISAV-B in the US and beyond?
Demand drivers
- 2-dose series adoption: Shorter series improves uptake where completion rates are a binding constraint in payer and provider workflow.
- Adult and risk population fit: HBV vaccination demand is structurally supported by ongoing screening and immunization programs for adults at risk (healthcare exposure, diabetes, kidney disease populations, and other occupational or clinical risk groups).
- Guideline alignment: Broad public health recommendations for HBV vaccination in adults with risk factors continue to sustain addressable market demand for effective vaccines.
Competitive landscape (US)
HEPLISAV-B competes against other licensed HBV vaccines and combination strategies used in adult immunization workflows. The differentiation that matters commercially is (1) protective antibody response rates, and (2) series length affecting completion and provider adherence.
How does HEPLISAV-B perform versus traditional 3-dose HBV vaccines in market terms?
HEPLISAV-B’s market performance is linked to its ability to convert prescriptions into fully vaccinated patients. In HBV programs, the 2-dose schedule is a commercial advantage in settings where follow-up dose adherence is inconsistent.
Business-relevant performance attributes
- Series length: 2 doses (improves completion and reduces scheduling friction).
- Immunogenicity: Stronger seroprotection outcomes are the clinical basis for payer and provider confidence, which supports formulary acceptance.
Clinical trial update: what changed recently?
There is no discrete, newly published global Phase 3 trial program in the open-facing regulatory and literature record that would materially reset HEPLISAV-B’s labeled position beyond prior pivotal evidence. Business impact since initial approval is driven by:
- ongoing usage in adult immunization under existing label,
- formulary and contracting dynamics,
- provider adoption in high-volume adult immunization pathways.
The clinical evidence foundation remains the pivotal seroprotection dataset and associated immunogenicity findings used for approval and labeling. [1]
Market Analysis: Where HEPLISAV-B sits today
What is the market size proxy for HBV vaccination in the main commercial region?
HEPLISAV-B is a segment within the broader hepatitis B vaccine market. The actionable market question is not only the total HBV vaccine volume, but also the share of adult high-risk vaccination where 2-dose vaccines can capture prescription share through completion and immunogenicity differentiation.
Allocation logic used for projection
Market share depends on:
- adult vaccination demand growth drivers (screening and adult risk vaccination programs),
- provider preference for series completion,
- payer contracting and price competitiveness among HBV vaccines.
What is the US adoption profile likely to be?
HEPLISAV-B’s profile aligns with adult immunization workflows in:
- primary care networks,
- occupational health settings,
- specialty clinics covering risk cohorts,
- hospital outpatient vaccination programs.
Adoption typically increases where 2-dose workflows reduce missed second doses and where immunogenicity evidence supports preference in patients with prior non-response or higher likelihood of lower response.
What is the commercialization risk map?
Key risks that can pressure uptake:
- pricing pressure among competing HBV vaccines,
- health system contracting changes affecting formulary mix,
- procurement consolidation shifting volume toward lowest net-cost products.
Key supports:
- completion advantage that reduces administrative loss,
- clinical immunogenicity differentiation that supports provider repeat prescribing.
Forecast: 2025–2035 market projection
How will demand evolve through 2035?
Projection framework (top-down with share-of-adult-risk logic)
Because HEPLISAV-B is a branded vaccine segment tied to adult vaccination behaviors and payer/provider contracting, the forecast is built on:
- growth in adult HBV immunization demand from ongoing risk-based programs,
- penetration of 2-dose vaccine convenience over time,
- competitive share stability tempered by price contracting.
Scenario outcomes (US-focused)
The forecast below expresses HEPLISAV-B growth in unit demand and revenue proxy terms, using scenario bands for adoption and contracting.
| Year |
Base case HEPLISAV-B demand trend |
Upside |
Downside |
| 2025 |
Stabilizing growth |
Higher adult uptake and better contracting |
Greater price compression |
| 2026 |
Continued expansion |
Faster migration to 2-dose pathways |
Slower formulary migration |
| 2027 |
Mid-cycle growth |
Stronger provider preference in risk cohorts |
Competitive bids reduce share |
| 2028 |
Growth moderates as market matures |
Premium over competitors sustains net price |
Sustained erosion |
| 2029 |
Low-to-moderate growth |
Increased cohort coverage |
Limited net price expansion |
| 2030–2035 |
Flat to modest growth |
Improved adult program coverage and adherence |
Ongoing price pressure |
Net result (directional): Base case shows low-to-mid single digit annual growth from 2025 into early 2030s, with upside driven by stronger formulary retention and patient completion rates, and downside driven by price and share pressure from alternative HBV vaccines.
What milestones will matter most for the forecast?
- formulary renewals in large health systems and payer networks,
- tender outcomes for adult immunization vaccine contracts,
- evidence-driven preference in populations where immunogenicity and completion are decisive.
Regulatory and evidence anchors (for diligence)
What does the FDA label confirm for clinical use?
The current prescribing information provides the labeled indication, age group, dosing schedule, and key clinical immunogenicity endpoints used for approval and ongoing clinical use. [1]
Key Takeaways
- HEPLISAV-B’s commercial case rests on 2-dose convenience and protective seroprotection performance demonstrated in pivotal clinical evidence used for FDA labeling. [1]
- Market growth is driven by adult HBV vaccination demand, where completion and immunogenicity differentiate vaccine choice.
- 2025–2035 outlook is base-case low-to-mid single digit growth with meaningful sensitivity to US formulary and procurement pricing/contracting outcomes rather than any new labeled clinical Phase 3 reset.
FAQs
-
Is HEPLISAV-B a 2-dose hepatitis B vaccine?
Yes. HEPLISAV-B is administered as a 2-dose series per labeled schedule. [1]
-
What endpoint defines success in HBV vaccine development for HEPLISAV-B?
The core endpoint is anti-HBs seroprotection at or above the labeled protective threshold after the vaccination series. [1]
-
Where does HEPLISAV-B see strongest commercial traction?
Adult immunization programs focused on risk populations where completion and immunogenicity drive vaccine selection. [1]
-
What is the main commercial risk to HEPLISAV-B revenue growth?
Net price and share pressure from competing HBV vaccines through contracting, tenders, and formulary mix. [1]
-
What is the long-term demand driver through 2035?
Ongoing adult HBV immunization and risk-based vaccination coverage in the US, where 2-dose adherence improves realized vaccination rates. [1]
References
[1] FDA. (n.d.). HEPLISAV-B prescribing information / label. U.S. Food and Drug Administration.
